Cargando…
Clinical follow-up on weight loss, glycemic control, and safety aspects of 24 months of duodenal-jejunal bypass liner implantation
BACKGROUND: The duodenal-jejunal bypass liner (DJBL) is an endoscopic device designed to induce weight loss and improve glycemic control. The liner is licensed for a maximum implant duration of 12 months. It might be hypothesized that extension of the dwelling time results in added value. The goals...
Autores principales: | Betzel, B., Cooiman, M. I., Aarts, E. O., Janssen, I. M. C., Wahab, P. J., Groenen, M. J. M., Drenth, J. P. H., Berends, F. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946747/ https://www.ncbi.nlm.nih.gov/pubmed/30877567 http://dx.doi.org/10.1007/s00464-019-06752-8 |
Ejemplares similares
-
Duodenal-jejunal bypass liner implantation provokes rapid weight loss and improved glycemic control, accompanied by elevated fasting ghrelin levels
por: Koehestanie, Parweez, et al.
Publicado: (2014) -
The Effect of 6 and 12 months Duodenal-Jejunal Bypass Liner Treatment on Obesity and Type 2 Diabetes: a Crossover Cohort Study
por: van Rijn, Selwyn, et al.
Publicado: (2017) -
The EndoBarrier: Duodenal-Jejunal Bypass Liner for Diabetes and Weight Loss
por: Ruban, Aruchuna, et al.
Publicado: (2018) -
Research Progress of Duodenal-Jejunal Bypass Liner in the Treatment of Obesity and Type 2 Diabetes Mellitus
por: Chen, Ji-Hua, et al.
Publicado: (2022) -
Endoscopic Duodenal-Jejunal Bypass Liner Treatment for Type 2 Diabetes and Obesity: Glycemic and Cardiovascular Disease Risk Factor Improvements in 1,022 Patients Treated Worldwide
por: Ryder, Robert E.J., et al.
Publicado: (2023)